Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

← catalyst calendar

NCT06268873 · readout in 553 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
2,554actual
Sites
565
Countries
Argentina, Australia, Belgium +35

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-03-29actualWhen the study began enrolling
Primary completion2028-02-24estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-02-24estimatedThe whole study's end, after follow-up
First posted2024-02-20actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-26actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Chronic Kidney Disease and Hypertension

Interventions

  • Drug: Baxdrostat/dapagliflozin — also filed as Baxdrostat CIN-107
  • Drug: Dapagliflozin in combination with placebo

Primary outcome

what the primary-completion date above is the date OF
To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR over time.
measured Baseline - 2 years + 12 weeks

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed